<span item_type="fundamental" item_id="93ff40c1d636f56caccd437559b5342d" counter_id="ST/US/BMRN" env="prod"></span><span item_type="announcement" item_id="604187420120646273" env="prod"></span><p>Revenue: As of FY2025, the actual value is USD 3.2 B, beating the estimate of USD 3.171 B.</p><p></p><h3>FY 2025 Revenue</h3><p>BioMarin Pharmaceutical Inc. expects its FY 2025 revenue to be approximately $3.2 billion, aligning with previous guidance of $3,150 million to $3,200 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1048477/000119312526010508/d93149dex991.htm"></span></p><h3>VOXZOGO Revenue</h3><p>Revenue from VOXZOGO is anticipated to be around $920 million, within the earlier guidance range of $900 million to $935 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1048477/000119312526010508/d93149dex991.htm"></span></p><h3>ROCTAVIAN Asset Write-Down</h3><p>The Q4 ROCTAVIAN asset write-down is estimated to be between $230 million and $260 million, impacting inventory, facilities, intangible assets, and severance costs. Approximately $120 million to $125 million of this write-down, equating to a - $0.60 to - $0.64 per share impact, is expected to reduce Non-GAAP Diluted EPS.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1048477/000119312526010508/d93149dex991.htm"></span></p><h3>Non-GAAP Financial Measures</h3><p>Non-GAAP Diluted EPS guidance, excluding the ROCTAVIAN asset write-down impact, remains unchanged due to the expected revenue result being partly offset by incremental Q4 operating expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1048477/000119312526010508/d93149dex991.htm"></span></p><h3>Outlook / Guidance</h3><p>BioMarin plans to exclude ROCTAVIAN revenue from its 2026 guidance. The company anticipates substantial accretion beginning in 2027 following the proposed acquisition of Amicus Therapeutics, which is expected to accelerate growth and diversify revenue. BioMarin aims to expand VOXZOGO for achondroplasia and add a second indication for hypochondroplasia in 2027, following the expected release of pivotal data in the first half of 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1048477/000119312526010508/d93149dex991.htm"></span></p>

BioMarin Pharma | 8-K: FY2025 Revenue Beats Estimate at USD 3.2 B